[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 30 of about 30
1. Nesher E, Greenberg R, Avital S, Skornick Y, Schneebaum S: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis. Isr Med Assoc J; 2007 Nov;9(11):787-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in peritoneal carcinomatosis.
  • BACKGROUND: Peritoneal carcinomatosis is an advanced form of cancer with poor prognosis that in the past was treated mainly palliatively.
  • Today, the definitive approach to peritoneal surface malignancy involves peritonectomy, visceral resection and perioperative intra-abdominal hyperthermic chemotherapy.
  • OBJECTIVES: To determine whether cytoreductive surgery and intraperitoneal hyperthermic chemotherapy can extend survival, and with minor complications only, in patients with peritoneal carcinomatosis.
  • METHODS: Twenty-two IPHP procedures were performed in 17 patients with peritoneal carcinomatosis in our institution between 1998 and 2007: 6 had pseudomyxoma peritonei, 5 had colorectal carcinoma, 3 had ovarian cancer and 3 had mesotheliomas.
  • Intraperitoneal chemotherapy was administered through four large catheters (2F) using a closed system of two pumps, a heat exchanger and two filters.
  • Six patients had minor complications (pleural effusion, leukopenia, fever, prolonged paralytic ileus, sepsis), two of which may be attributed to chemotherapy toxicity (leukopenia).
  • CONCLUSIONS: IPHP is a safe treatment modality for patients with peritoneal carcinomatosis.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Hyperthermia, Induced. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / secondary. Adult. Aged. Colonic Neoplasms / pathology. Combined Modality Therapy. Female. Humans. Male. Mesothelioma / secondary. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085034.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Kianmanesh R, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, Hay JM, Flamant Y, Msika S: Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg; 2007 Apr;245(4):597-603

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases.
  • INTRODUCTION: The aim of this study was to evaluate the results of an aggressive strategy in patients presenting peritoneal carcinomatosis (PC) from colorectal cancer with or without liver metastases (LMs) treated with cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • Eleven patients (25%) presented occlusion at the time of PC diagnosis.
  • Seventeen patients (39%) presented one or multiple complications (per procedure morbidity = 31%).
  • Complications included deep abscess (n = 6), wound infection (n = 5), pleural effusion (n = 5), digestive fistula (n = 4), delayed gastric emptying syndrome (n = 4), and renal failure (n = 3).
  • CONCLUSION: Iterative CS + HIPEC is an effective treatment in PC from colorectal cancer.
  • The presence of resectable LMs associated with PC does not contraindicate the prospect of an oncologic treatment in these patients.
  • [MeSH-major] Colonic Neoplasms / pathology. Peritoneal Neoplasms / drug therapy. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Hyperthermia, Induced. Infusions, Parenteral. Liver Neoplasms / secondary. Male. Middle Aged. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 9):S118-22 [16399448.001]
  • [Cites] N Engl J Med. 2006 Jan 5;354(1):34-43 [16394300.001]
  • [Cites] Gastroenterol Clin Biol. 2005 Oct;29(10):1010-3 [16435508.001]
  • [Cites] J Gastrointest Surg. 2006 Feb;10(2):240-8 [16455457.001]
  • [Cites] Eur J Surg Oncol. 2006 Aug;32(6):632-6 [16621428.001]
  • [Cites] Ann Surg Oncol. 1999 Dec;6(8):790-6 [10622509.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):71-6 [11443611.001]
  • [Cites] Ann Surg. 2001 Aug;234(2):198-205 [11505065.001]
  • [Cites] Oncology. 2002;63(4):346-52 [12417789.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):799-806 [12610177.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):164-70 [12831938.001]
  • [Cites] Scand J Surg. 2003;92(2):178-9 [12841562.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3737-43 [14551293.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):531-41 [14567016.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):543-59 [14567017.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):178-86 [14761921.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):165-82 [15000156.001]
  • [Cites] Br J Surg. 2004 Apr;91(4):455-6 [15048746.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):518-21 [15123461.001]
  • [Cites] Br J Surg. 2004 Jun;91(6):747-54 [15164446.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):278-85 [15273552.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3284-92 [15310771.001]
  • [Cites] Eur J Surg Oncol. 2004 Oct;30(8):864-8 [15336733.001]
  • [Cites] Surgery. 1993 Jun;113(6):631-6 [8506520.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] World J Surg. 1995 Mar-Apr;19(2):235-40 [7754629.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2622-9 [8640714.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2317-21 [10472351.001]
  • [Cites] Bull Cancer. 2004 May;91(5):E113-32 [15568226.001]
  • [Cites] Curr Opin Obstet Gynecol. 2005 Feb;17(1):83-6 [15711417.001]
  • [Cites] Cancer Invest. 2005;23(2):155-72 [15813509.001]
  • [Cites] Ann Surg Oncol. 2005 Jan;12(1):65-71 [15827780.001]
  • [Cites] Curr Opin Oncol. 2005 Jul;17(4):397-9 [15933477.001]
  • [Cites] Tech Coloproctol. 2005 Jul;9(2):95-103 [16007367.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):212-22 [16432354.001]
  • (PMID = 17414609.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1877034
  •  go-up   go-down


3. Zhang X, Varin E, Briand M, Allouche S, Heutte N, Schwartz L, Poulain L, Icard P: Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice. Anticancer Res; 2009 Apr;29(4):1443-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapy for malignant pleural mesothelioma based on anti-energetic effect: an experimental study using 3-Bromopyruvate on nude mice.
  • MATERIALS AND METHODS: The effect of 3-Bromopyruvate (3-BrPA) alone or associated to cisplatin on nude mice presenting intraperitoneal carcinomatosis developed after intraperitoneal injection of human mesothelioma cells (MSTO-211H) was investigated.
  • CONCLUSION: 3-BrPA may thus constitute an interesting novel anticancer drug that could be tested in humans.
  • [MeSH-major] Enzyme Inhibitors / pharmacology. Mesothelioma / drug therapy. Oxygen Consumption / drug effects. Peritoneal Neoplasms / drug therapy. Pleural Neoplasms / drug therapy. Pyruvates / pharmacology
  • [MeSH-minor] Animals. Cisplatin / pharmacology. Energy Metabolism. Female. Humans. Mice. Mice, Nude. Mitochondria / drug effects. Mitochondria / metabolism. Pyruvate Dehydrogenase Complex / antagonists & inhibitors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19414400.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Pyruvate Dehydrogenase Complex; 0 / Pyruvates; 63JMV04GRK / bromopyruvate; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Kunitomo K, Inoue S, Ichihara F, Kono K, Fujii H, Matsumoto Y, Ooi A: A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel. Hum Pathol; 2004 Mar;35(3):379-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-one months later, massive liver metastases and pleural carcinomatosis occurred.
  • The liver metastases responded completely to chemotherapy with trastuzumab combined with docetaxel, but the pleural carcinomatosis was refractory to the therapy.
  • This analysis also detected a single cell with HER2 amplification in the pleural effusion that was taken at the completion of the chemotherapy, but four follow-up tests showed no amplified cells.
  • However, in the pleural effusion, the effect of trastuzumab was more specific to HER2-amplified cells and caused outgrowth of cancer cells lacking expression of HER2 receptors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Phytogenic / therapeutic use. Biomarkers, Tumor / metabolism. Fatal Outcome. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Taxoids / administration & dosage. Tomography, X-Ray Computed. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15017597.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 0 / Taxoids; 15H5577CQD / docetaxel; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


5. Fujiki H, Kumano T, Yasuoka R, Sonoyama Y, Morita S, Mitsuo M, Oda T, Kadotani Y: [A case of scirrhous carcinoma of the stomach with malignant pleural and peritoneal carcinomatosis responding to the local administration of docetaxel (TXT)]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1849-51
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of scirrhous carcinoma of the stomach with malignant pleural and peritoneal carcinomatosis responding to the local administration of docetaxel (TXT)].
  • Despite adjuvant chemotherapy with TS-1 and/or CDDP, ascites caused by peritoneal carcinomatosis increased four months after gastrectomy.
  • This therapy successfully maintained her good quality of life by inhibiting the increase of ascites without any severe adverse side effects for more than six months.
  • When the left effusion from pleural carcinomatosis appeared nine months after the surgery, the intrathoracic administration of TXT succeeded in inhibiting the increase of pleural effusion over five months or more.
  • We thought that the local administration of TXT was a useful treatment without severe toxicities for malignant pleural effusion and ascites in scirrhous carcinoma of the stomach.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Adenocarcinoma, Scirrhous / secondary. Antineoplastic Agents, Phytogenic / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Peritonitis / drug therapy. Pleural Neoplasms / drug therapy. Pleural Neoplasms / secondary. Stomach Neoplasms / pathology. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Ascites / drug therapy. Ascites / etiology. Female. Gastrectomy. Humans. Infusions, Intravenous. Infusions, Parenteral. Pleural Effusion / drug therapy. Pleural Effusion / etiology. Quality of Life. Thoracic Cavity

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel
  •  go-up   go-down


6. Akiyama T, Homma H, Mezawa S, Takahashi S, Koike K, Kogawa K, Hirata K: [Intraperitoneal and intrapleural gemcitabine in patients with advanced pancreatic cancer]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1712-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed intraperitoneal and intrapleural dosing gemcitabine (GEM) to eight patients with advanced pancreatic cancer having peritoneal or pleural carcinomatosis and evaluated its actions and safety.
  • GEM (500 mg/m2) was infused into the abdominal cavity or thoracic cavity after drainage of peritoneal or pleural effusion.
  • Then, we repeated the GEM administration observing their systematic symptoms and evaluated the alteration of peritoneal or pleural effusion and cytology.
  • In three of the five cases of peritoneal carcinomatosis, intraperitoneal administration revealed a decrease of peritoneal effusion.
  • In two of the three cases of pleural carcinomatosis, intrapleural administration revealed a decrease of pleural effusion.
  • Intraperitoneal and intrapleural dosing GEM had minor side effects and could improve QOL for the patients with advanced pancreatic cancer associated with peritoneal or pleural carcinomatosis.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma / drug therapy. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Infusions, Intravenous. Infusions, Parenteral. Male. Middle Aged. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / secondary. Pleural Cavity. Pleural Neoplasms / drug therapy. Pleural Neoplasms / secondary

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315917.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


7. Mousavi AS, Mazhari MM, Guilani MM, Ghaemmaghami F, Behtash N, Akhavan S: Can primary optimal cytoreduction be predicted in advanced epithelial ovarian cancer preoperatively? World J Surg Oncol; 2010;8:11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients with advanced epithelial ovarian cancer who underwent surgery for the first time from Jan. to June 2008 at gynecologic oncology ward of TUMS (Tehran University of Medical Sciences) were eligible for this study.
  • Variables were peritoneal carcinomatosis, serum CA125, ascites, pleural effusion, physical status and imaging findings.Univariate comparisons of patients underwent suboptimal cytoreduction carried out using Fisher's exact test for each of the potential predictors.
  • Statistically significant association was noted between peritoneal carcinomatosis and suboptimal cytoreduction.
  • There were no statistically significant differences between physical status, pleural effusion, imaging findings, serum CA125 and ascites of individuals with optimal cytoreduction compared to those with suboptimal cytoreduction.
  • Only the patient who is most unlikely to undergo optimal cytoreduction should be offered neoadjuvant chemotherapy, unless her medical condition renders her unsuitable for primary surgery.
  • [MeSH-minor] Ascites. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Female. Humans. Neoplasm Staging. Pleural Effusion. Preoperative Care. Prognosis. Prospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2003;65(4):316-22 [14707451.001]
  • [Cites] J Am Coll Surg. 2003 Dec;197(6):955-63 [14644284.001]
  • [Cites] Gynecol Oncol. 2004 Nov;95(2):377-83 [15491760.001]
  • [Cites] Obstet Gynecol. 1986 Jun;67(6):783-8 [3010203.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):159-66 [1468693.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):166-72 [8418230.001]
  • [Cites] Am J Obstet Gynecol. 1994 Apr;170(4):974-9; discussion 979-80 [8166218.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 2):S91-6 [7835815.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):629-34 [7845426.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(5):393-6 [8933839.001]
  • [Cites] Gynecol Oncol. 1998 May;69(2):103-8 [9600815.001]
  • [Cites] Gynecol Oncol. 1998 Dec;71(3):431-6 [9887245.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):93-9 [9889037.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):496-500 [16681717.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):384-9 [17264334.001]
  • [Cites] Cancer. 2001 Jun 15;91(12):2329-34 [11413522.001]
  • [Cites] Gynecol Oncol. 2001 Sep;82(3):489-97 [11520145.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Int J Gynecol Cancer. 2001 Nov-Dec;11(6):466-70 [11906550.001]
  • [Cites] Gynecol Oncol. 2003 Jan;88(1):9-16 [12504620.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Gynecol Cancer. 2003 Mar-Apr;13(2):120-4 [12657110.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):423-30 [15228414.001]
  • (PMID = 20170515.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  • [Other-IDs] NLM/ PMC2844392
  •  go-up   go-down


8. Kimura M, Kaneda H, Kume S, Matsushita H, Inoue M, Kai M, Takeuchi H, Uemura K: [A preliminary report on the treatment of pleural carcinomatosis with SMANCS]. Gan To Kagaku Ryoho; 2001 Jul;28(7):1023-5
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A preliminary report on the treatment of pleural carcinomatosis with SMANCS].
  • To clarify the effect of SMANCS on malignant pleural carcinomatosis, seven patients with malignant pleural effusion were treated with SMANCS administered via an intracavitary route.
  • Five patients showed improvement after one or two injections of SMANCS into the thoracic cavity, although 2 patients needed further therapy with the immunopotentiating agent picibanil (OK-432).
  • This simple therapeutic tactic with SMANCS may be effective in cases of malignant pleural carcinomatosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Maleic Anhydrides / therapeutic use. Pleural Effusion, Malignant / drug therapy. Polystyrenes / therapeutic use. Zinostatin / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11478133.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Maleic Anhydrides; 0 / Polystyrenes; 0 / poly(maleic acid-styrene)neocarzinostatin; 9014-02-2 / Zinostatin
  •  go-up   go-down


9. Kaira K, Takise A, Endou K, Yanagitani N, Sunaga N, Mori M: A case of primary peritoneal serous papillary carcinoma initially presented by massive bilateral pleural effusions. Eur J Gynaecol Oncol; 2006;27(2):197-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary peritoneal serous papillary carcinoma initially presented by massive bilateral pleural effusions.
  • In a state of small amounts of ascites, initial manifestation of massive bilateral pleural effusion is unusual.
  • Chest radiograph showed a massive bilateral pleural effusion.
  • Chest computed tomography (CT) revealed irregular pleural thickening and a small amount of ascites.
  • Adenocarcinoma cells were found via cytologic examination in bilateral pleural fluids and ascites.
  • Because the primary site of the adenocarcinoma was not found, a surgical biopsy of the right pleural thickening was performed.
  • The patient was treated with platinum-based chemotherapy.
  • Physicians should be aware of a possibility of PSPC when the radiographic findings show massive bilateral pleural effusion due to pleural carcinomatosis, with high serum levels of CA125.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / drug therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / drug therapy. Pleural Effusion / diagnosis
  • [MeSH-minor] Aged. CA-125 Antigen / blood. Female. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620072.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


10. Morisaki T, Matsumoto K, Kuroki H, Kubo M, Baba E, Onishi H, Tasaki A, Nakamura M, Inaba S, Katano M: Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion. Anticancer Res; 2003 Nov-Dec;23(6a):4459-65
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have conducted a pilot study with combined immunotherapy using autologous lymphocytes activated ex vivo and monocyte-derived dendritic cells in combination with low-dose OK-432, a streptococcal preparation, in five patients with peritoneal or pleural carcinomatosis who were resistant to standard chemotherapy.
  • The overall prognosis of the patients was acceptable and the mean survival time was more than 9 months.
  • The locoregional immunotherapy seems to be encouraging in view of therapeutic modality in patients who are resistant to standard chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Ascitic Fluid / therapy. Dendritic Cells / immunology. Immunotherapy, Adoptive / methods. Picibanil / therapeutic use. Pleural Effusion, Malignant / therapy. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / pathology. Combined Modality Therapy. Female. Humans. Lymphocyte Activation / immunology. Middle Aged. Pancreatic Neoplasms / pathology. Pilot Projects. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14666734.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 39325-01-4 / Picibanil
  •  go-up   go-down


11. Katano K, Tsujitani S, Maeta M, Fukuda K, Oka S, Hisamitsu K, Ikeguchi M, Kaibara N: Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in cases of esophageal cancer. Oncol Rep; 2001 May-Jun;8(3):605-9
Hazardous Substances Data Bank. PLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of intraoperative intrapleural cisplatin chemotherapy of various osmolarities in cases of esophageal cancer.
  • Intraoperative intrapleural (i.pl.) cisplatin (CDDP) treatment during thoracotomy was performed for esophageal cancers.
  • Three patients underwent isotonic (308 mOsm/l) CDDP treatment.
  • Hypotonic CDDP treatments with a 154 mOsm/l solution and a 62 mOsm/l solution were administered to 4 and 9 patients, respectively.
  • The area under the curve of concentration versus time (AUC) of the plasma of the 62 mOsm/l solution was significantly higher than that of the 154 mOsm/l and isotonic solution.
  • CDDP is tolerable and may be useful for treatment of the incipient phase of pleural carcinomatosis and for prophylaxis of postoperative recurrence.

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11295088.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypotonic Solutions; 49DFR088MY / Platinum; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Rossi CR, Pilati P, Mocellin S, Foletto M, Ori C, Innocente F, Nitti D, Lise M: Hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from gastric adenocarcinoma. Suppl Tumori; 2003 Sep-Oct;2(5):S54-7
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from gastric adenocarcinoma.
  • BACKGROUND: Patients with peritoneal carcinomatosis from gastric carcinoma have a dismal prognosis.
  • Hyperthermic intraperitoneal intraoperative chemotherapy (HIIC) has been proposed to treat residual disease after cytoreductive surgery.
  • PATIENTS AND METHODS: From January 1998 through July 2002, 13 patients with peritoneal carcinomatosis from gastric cancer underwent complete cytoreductive surgery followed by HIIC.
  • Postoperative complication rate was 26% (pleural effusion, n = 4; septicemia = 1).
  • CONCLUSIONS: Cytoreductive surgery followed by HIIC resulted a feasible procedure, the overall morbidity rate being acceptable.
  • Although the study was conducted in a subset of patients with peritoneal carcinomatosis from gastric cancer (resectable disease), survival results are encouraging.
  • [MeSH-major] Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hyperthermia, Induced. Infusions, Parenteral / methods. Peritoneal Neoplasms / therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12914393.001).
  • [ISSN] 2283-5423
  • [Journal-full-title] I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.]
  • [ISO-abbreviation] Suppl Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Murata S, Naito H, Yamamoto H, Mekata E, Shimizu T, Shiomi H, Naka S, Abe H, Kurumi Y, Tani T: Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15588

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of adjuvant hyperthermic intraperitoneal chemotherapy with three drugs for the prophylactic treatment of carcinomatosis after resection of advanced gastric cancer.
  • : e15588 Background: This prospective study was performed to assess the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) with three drugs in patients with curative resection of T3 or T4 advanced gastric cancer.
  • Patients were given an adjuvant S-1 treatment after surgery.
  • Three patients with pT3 had recurrence of pleural dissemination (n=1), lymph node metastases (n=1), or pulmonary metastases and peritoneal dissemination (n=1).
  • CONCLUSIONS: The present study suggests that HIPEC with three drugs after curative resection of advanced gastric primary cancer is associated with improved overall survival with an acceptable morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962346.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Park YH, Ryoo BY, Choi SJ, Kim HT: Paclitaxel plus cisplatin in cancer of unknown primary site (CUP). J Clin Oncol; 2004 Jul 15;22(14_suppl):2123

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was designed to evaluate the efficacy and toxicity of paclitaxel / cisplatin combination chemotherapy in patients with CUP.
  • The patients received a total of 138 cycles of chemotherapy.
  • The median number of cycles of chemotherapy per patient was 4.
  • Initial presentations were cervical lymphadenopathy, peritoneal carcinomatosis, liver mass, pelvic mass, metastatic bone tumor and pleural effusion.
  • Median time to progression was 4 (95% C.I., 1.3-6.8) months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017099.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Elias D, Sideris L, Liberale G, Ducreux M, Malka D, Lasser P, Duvillard P, Baudin E: Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas. Surgery; 2005 Apr;137(4):411-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of peritoneal carcinomatosis from well-differentiated digestive endocrine carcinomas.
  • BACKGROUND: The presence of peritoneal carcinomatosis (PC) in association with endocrine carcinomas (EC) is generally considered to have no impact on life expectancy, contrary to liver metastases.
  • This study was aimed at assessing the actual prognostic impact of PC and to evaluate a new treatment with respect to survival times.
  • Patients in group 1 (n = 20) could not undergo complete resection of PC, while those in group 2 (n = 17) underwent complete cytoreductive surgery, followed by immediate intraperitoneal chemotherapy.
  • When present, PC is the direct cause of death in 40% of patients if no specific treatment is undertaken.
  • Treatment of PC with maximal cytoreductive surgery and immediate intraperitoneal chemotherapy appears promising, even though it can only be considered as palliative.
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / secondary. Disease Progression. Disease-Free Survival. Humans. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymphatic Metastasis. Middle Aged. Pleural Neoplasms / secondary. Recurrence. Retrospective Studies. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Surgery. 2005 Apr;137(4):417-8 [15800488.001]
  • (PMID = 15800487.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Gushchin V, Demmy TL, Kane JM 3rd: Surgical management of metastatic peritoneal or pleural disease. Semin Oncol; 2007 Jun;34(3):215-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of metastatic peritoneal or pleural disease.
  • The surgeon's role in the treatment of malignant peritoneal disease has expanded over time, stemming from a better understanding of tumor biology.
  • For the majority of patients, carcinomatosis is a terminal process with surgical intervention being reserved for palliation of bowel obstruction or symptomatic ascites.
  • This review describes the patterns of peritoneal tumor dissemination, surgical palliation of malignant bowel obstruction or ascites, and the principles, indications, toxicities, and overall results of cytoreductive surgery with intraperitoneal hyperthermic chemotherapy.
  • On the other hand, long-term survival is rarely expected for malignant pleural disease unless the causal tumor is highly responsive to systemic chemotherapy.
  • There are controversies and considerable geographic variations in the management of malignant pleural effusions.
  • However, less invasive ambulatory palliative treatments for patients so afflicted are gaining popularity.
  • [MeSH-major] Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Pleural Neoplasms / secondary. Pleural Neoplasms / surgery
  • [MeSH-minor] Ascites / etiology. Ascites / surgery. Chemotherapy, Cancer, Regional Perfusion / adverse effects. Combined Modality Therapy. Drainage / methods. Humans. Intestinal Obstruction / etiology. Intestinal Obstruction / surgery. Palliative Care. Pleural Effusion / etiology. Pleural Effusion / therapy. Prognosis. Sclerotherapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560983.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 105
  •  go-up   go-down


17. Reuter NP, Macgregor JM, Woodall CE, Sticca RP, William C, Helm MB, Scoggins CR, McMasters KM, Martin RC: Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy. Am J Surg; 2008 Dec;196(6):909-13; discussion 913-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy.
  • BACKGROUND: Peritoneal carcinomatosis has a typical natural history of bowel obstruction and death.
  • Significant evidence suggests that cytoreduction with heated intraperitoneal chemotherapy (HIPEC) improves long-term survival for these tumors.
  • METHODS: A retrospective case series of patients who underwent initial HIPEC treatment was performed at 2 moderate-volume centers.
  • Pleural effusion and wound infection were the most common complications.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Colonic Neoplasms / drug therapy. Hyperthermia, Induced / methods. Peritoneal Neoplasms / drug therapy. Preoperative Care / methods. Pseudomyxoma Peritonei / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Injections. Middle Aged. Peritoneal Cavity. Retrospective Studies. Severity of Illness Index. Survival Rate. Treatment Outcome. United States / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19095108.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


18. Sugarbaker PH: Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy. Int J Hyperthermia; 2007 Aug;23(5):431-42
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy.
  • Intraoperative chemotherapy with heat has been identified as a treatment option for patients with cancer spread to peritoneal surfaces.
  • This treatment modality is viewed as a supplement to several other treatments for this group of patients including cytoreductive surgery, systemic chemotherapy, early postoperative intraperitoneal chemotherapy, and long-term bidirectional chemotherapy.
  • The pharmacologic basis for using heat to supplement chemotherapy effects are related to the increased penetration of chemotherapy into tumor with hyperthermia, the delayed clearance of chemotherapy from the peritoneal cavity after direct instillation, and an increased cytotoxicity that has been documented with selected chemotherapy agents.
  • Data to support the use of perioperative hyperthermic intraperitoneal chemotherapy with mucinous appendiceal carcinomatosis comes from a large number of single institution phase II studies.
  • Also, peritoneal and pleural mesothelioma are benefited.
  • In colon cancer carcinomatosis, large phase II multi-institutional trials and a single phase III trial documented an increased median survival of these patients from approximately 1 year to over 2 years.
  • Prophylaxis against peritoneal carcinomatosis in gastric cancer has been demonstrated in phase III trials.
  • In ovarian cancer the rationale for this treatment remains large but its current application is limited.
  • Much work needs to be done to identify a proper clinical perspective on hyperthermia used with chemotherapy in patients with peritoneal surface malignancy.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Hyperthermia, Induced / methods. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Doxorubicin / administration & dosage. Doxorubicin / pharmacokinetics. Female. Gastrointestinal Neoplasms / drug therapy. Genital Neoplasms, Female / drug therapy. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17701534.001).
  • [ISSN] 0265-6736
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin
  • [Number-of-references] 53
  •  go-up   go-down


19. Van der Speeten K, Stuart OA, Mahteme H, Sugarbaker PH: A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin. Cancer Chemother Pharmacol; 2009 Apr;63(5):799-805
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin.
  • PURPOSE: A pharmacologic analysis of intracavitary doxorubicin in the treatment of patients with intracavitary cancer dissemination was performed to further evaluate the possible benefits of this treatment modality.
  • METHODS: Twenty appendiceal malignancy patients with peritoneal carcinomatosis (PC), three appendiceal malignancy patients with direct extension into the pleural cavity, 20 patients with peritoneal mesothelioma and one patient with pleural mesothelioma were available for pharmacologic monitoring.
  • After intrapleural administration, plasma and pleural fluid samples were collected at similar intervals.
  • Tumor and normal tissues were obtained when available.
  • Doxorubicin concentrations in tumor tissue were consistently elevated above intraperitoneal concentrations from 30 through 90 min.
  • Pleural chemotherapy solutions retained doxorubicin to a greater extent than peritoneal fluid.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Appendiceal Neoplasms / drug therapy. Chemotherapy, Cancer, Regional Perfusion. Doxorubicin / therapeutic use. Mesothelioma / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Ascitic Fluid / metabolism. Ascitic Fluid / pathology. Chromatography, High Pressure Liquid. Combined Modality Therapy. Female. Humans. Infusions, Parenteral. Intraoperative Period. Male. Middle Aged. Peritoneal Cavity / pathology. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654746.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin
  •  go-up   go-down


20. Yamagishi Y, Akiba Y, Izumiya M, Higuchi H, Iizuka H, Takaishi H, Nagata H, Hibi T: [A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1167-70
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy].
  • Here we report a case of type 4 gastric cancer associated with lymphangitis carcinomatosis which became refractory to the previous chemotherapies.
  • Disease activity has been well controlled until this time.
  • Since recurrence of left pleural effusion and lymphangitis carcinomatosis was recognized, we changed the chemotherapy TS-1 plus CPT-11.
  • Pleural effusion decreased and lymphangitis carcinomatosis improved.
  • The serum CA 19-9 level rose transiently after CPT-11 administration, and tended to fall at the second week of chemotherapy.
  • TS-1 plus CPT-11 combination chemotherapy would be effective for lymphangitis carcinomatosis and also useful as third-line chemotherapy for recurrent gastric cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Krukenberg Tumor / surgery. Lymphangitis / complications. Ovarian Neoplasms / surgery. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Drug Combinations. Female. Humans. Oxonic Acid / administration & dosage. Pyridines / administration & dosage. Tegafur / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121922.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


21. Akamatsu M, Tsuji Y, Nakata W, Ohmae T, Ohata K, Matsubara S, Katamoto T: [A patient with recurrent sigmoid colon cancer in whom pleural effusion and ascites resolved after FOLFOX 4 therapy]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2305-7
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with recurrent sigmoid colon cancer in whom pleural effusion and ascites resolved after FOLFOX 4 therapy].
  • We performed combination therapy with oxaliplatin/l-LV/5-FU (FOLFOX 4) in a patient with recurrent colorectal cancer (a 58-year-old man) who had pleural effusion and ascites.
  • This resulted in disappearance of the pleural effusion and ascites, as well as negative tumor markers.
  • The patient was diagnosed as having peritonitis carcinomatosis associated with recurrent sigmoid colon cancer, and was treated with FOLFOX 4.
  • CEA was 134.9 ng/mL before treatment, but became negative after six courses, while his pleural effusion and ascites disappeared after 10 courses of treatment.
  • This treatment also appeared to be useful for recurrent colorectal cancer with peritoneal dissemination.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / drug therapy. Pleural Effusion / drug therapy. Sigmoid Neoplasms / drug therapy
  • [MeSH-minor] Fluorouracil / therapeutic use. Humans. Leucovorin / therapeutic use. Male. Middle Aged. Neoplasm Recurrence, Local. Organoplatinum Compounds / therapeutic use

  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079636.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


22. Alonso O, Sugarbaker PH: Adult respiratory distress syndrome occurring in two patients undergoing cytoreductive surgery plus perioperative intraperitoneal chemotherapy: case reports and a review of the literature. Am Surg; 2000 Nov;66(11):1032-6
MedlinePlus Health Information. consumer health - After Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult respiratory distress syndrome occurring in two patients undergoing cytoreductive surgery plus perioperative intraperitoneal chemotherapy: case reports and a review of the literature.
  • Cytoreductive surgery and perioperative intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil may be considered as an accepted treatment for appendiceal malignancy with mucinous peritoneal carcinomatosis or for pseudomyxoma peritonei.
  • An extensive clinical review of two patients who had a clinical course compatible with acute respiratory distress syndrome without obvious cause except for the cytoreductive surgery and perioperative intraperitoneal chemotherapy itself was undertaken.
  • These two patients developed gradually increasing respiratory distress in the postoperative period.
  • These two patients were unusual in that they had extensive cytoreduction, maximal heat with the mitomycin C chemotherapy, and perfusion of both the abdominal cavity and the right pleural space.
  • We conclude that aggressive cytoreductive surgery plus perioperative intraperitoneal and intrapleural chemotherapy was associated with life-endangering respiratory failure in two patients.
  • It is possible that this aggressive approach to appendix malignancy with carcinomatosis is sufficiently traumatic to be considered a cause of adult respiratory distress syndrome.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Antineoplastic Agents / adverse effects. Appendix. Carcinoma / drug therapy. Carcinoma / surgery. Cecal Neoplasms / drug therapy. Cecal Neoplasms / surgery. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / surgery. Postoperative Complications / etiology. Respiratory Distress Syndrome, Adult / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11090013.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 12
  •  go-up   go-down


23. Tucakovic M, Bascom R, Bascom PB: Pulmonary medicine and palliative care. Best Pract Res Clin Obstet Gynaecol; 2001 Apr;15(2):291-304
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant pleural effusion is a poor prognostic factor: management options include repeated thoracentesis, chemical pleurodesis, symptomatic relief of dyspnoea with oxygen and morphine, and external drainage.
  • Parenchymal metastases are typically multifocal and respond to chemotherapy, with a limited role for pulmonary metastatectomy.
  • Pulmonary tumour embolism is frequently associated with lymphangitic carcinomatosis, and is most common in choriocarcinoma.
  • Non-pharmacological therapies include energy conservation, home redesign, and dyspnoea relief strategies, including pursed lip breathing, relaxation, oxygen, circulation of air with a fan, and attention to spiritual suffering.
  • Identification and treatment of gastroesophageal reflux, sinusitis, and asthma can improve many patients' coughs.
  • [MeSH-major] Genital Neoplasms, Female / complications. Genital Neoplasms, Female / therapy. Lung Diseases / etiology. Palliative Care / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Airway Obstruction / therapy. Cough / therapy. Dyspnea / therapy. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Meige Syndrome / surgery. Pleural Effusion, Malignant / therapy. Pulmonary Embolism / diagnosis. Pulmonary Embolism / drug therapy. Quality of Life. Vena Cava Filters

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Harcourt Publishers Ltd.
  • (PMID = 11358403.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


24. Briasoulis E, Kalofonos H, Bafaloukos D, Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C, Kosmidis P, Pavlidis N: Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol; 2000 Sep;18(17):3101-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment courses were repeated every 3 weeks to a maximum of eight cycles.
  • Thirty-three patients presented with liver, bone, or multiple organ metastases, 23 with predominantly nodal/pleural disease, and 19 (16 women) with peritoneal carcinomatosis.
  • The response rates and median survival times in the three clinically defined subsets were 47.8% and 13 months, respectively, for patients with predominantly nodal/pleural disease, 68.4% and 15 months, respectively, in women with peritoneal carcinomatosis, and 15.1% and 10 months, respectively, in patients with visceral or disseminated metastases.
  • Chemotherapy was well-tolerated.
  • CONCLUSION: Carboplatin plus paclitaxel combination chemotherapy is effective in patients with predominantly nodal/pleural metastases of unknown primary carcinoma and in women with peritoneal carcinomatosis.
  • The investigation of novel treatment approaches is highly warranted for this group of patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / drug therapy. Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adult. Aged. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / drug therapy. Drug Administration Routes. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10963638.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 143011-72-7 / Granulocyte Colony-Stimulating Factor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


25. Miyahara H, Itou H, Sekine A, Taniyama D, Katsui T, Tanaka W, Satou R, Kurihara A, Satou Y, Sakamaki F: [A case of adult T-cell leukemia/lymphoma with primary lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):342-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mass was pathologically diagnosed as adult T-cell leukemia/lymphoma (ATLL) because of a high HTLV-1 antibody titer, and radiation therapy was started.
  • The primary lesion was the lungs, with bilateral pleural effusion and lymphangitis carcinomatosis.
  • We diagnosed stage IV primary lung cancer and started chemotherapy.
  • However, he developed dyspnea due to pleural effusion and his performance status gradually decreased to 3.

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455967.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


26. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer; 2003 Sep;39(14):1990-2005
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic management of cancer of an unknown primary.
  • Patients with CUP present with metastatic disease for which the site of origin cannot be identified at the time of diagnosis.
  • The following clinicopathological entities have been recognised: (i) metastatic CUP primarily to the liver or to multiple sites, (ii) metastatic CUP to lymph nodes including the sub-sets involving primarily the mediastinal-retroperitoneal, the axillary, the cervical or the inguinal nodes, (iii) metastatic CUP of peritoneal cavity including the peritoneal papillary serous carcinomatosis in females and the peritoneal non-papillary carcinomatosis in males or females, (iv) metastatic CUP to the lungs with parenchymal metastases or isolated malignant pleural effusion, (v) metastatic CUP to the bones, (vi) metastatic CUP to the brain, (vii) metastatic neuroendocrine carcinomas and (viii) metastatic melanoma of an unknown primary.
  • Extensive work-up with specific pathology investigations (immunohistochemistry, electron microscopy, molecular diagnosis) and modern imaging technology (computed tomography (CT), mammography, Positron Emission Tomography (PET) scan) have resulted in some improvements in diagnosis; however, the primary site remains unknown in most patients, even on autopsy.
  • Several favourable sub-sets of CUP have been identified, which are responsive to systemic chemotherapy and/or locoregional treatment.
  • Identification and treatment of these patients is of paramount importance.
  • The considered responsive sub-sets to platinum-based chemotherapy are the poorly differentiated carcinomas involving the mediastinal-retroperitoneal nodes, the peritoneal papillary serous adenocarcinomatosis in females and the poorly differentiated neuroendocrine carcinomas.
  • Other tumours successfully managed by locoregional treatment with surgery and/or irradiation are the metastatic adenocarcinoma of isolated axillary nodes, metastatic squamous cell carcinoma of cervical nodes, or any other single metastatic site.
  • Empirical chemotherapy benefits some of the patients who do not fit into any favourable sub-set, and should be considered in patients with a good performance status.
  • [MeSH-major] Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2004 Jun;40(9):1454-5 [15177507.001]
  • (PMID = 12957453.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 119
  •  go-up   go-down


27. Oguri T, Ito S, Morishita M, Sakamoto K, Kondo M, Hasegawa Y: [Miliary tuberculosis and tuberculous peritonitis during infliximab treatment for rheumatoid arthritis]. Nihon Kokyuki Gakkai Zasshi; 2010 Mar;48(3):192-7
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Miliary tuberculosis and tuberculous peritonitis during infliximab treatment for rheumatoid arthritis].
  • A CT scan showed massive ascites, bilateral pleural effusion, disseminated granular shadows in the lung, and multiple swollen mediastinal lymph nodes.
  • A FDG-PET/CT scan showed increases of FDG uptake in the mesentery and peritoneum, mimicking peritoneal carcinomatosis.
  • Subsequent pleural and peritoneal fluid analysis showed elevated adenosine deaminase activity levels with no malignant cells.
  • A right pleural biopsy specimen revealed Langhans giant cells and granulomas.
  • Several weeks after a standard anti-tuberculosis regimen with 4 drugs was initiated, her clinical condition and radiological findings ameliorated.
  • Since the initial manifestations of tuberculosis tend to be more severe during treatment of rheumatoid arthritis with tumor necrosis factor-alpha inhibitors such as infliximab due to immune suppression, we should pay closer attention to the possibility of tuberculosis infection in these patients.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Antirheumatic Agents / adverse effects. Arthritis, Rheumatoid / drug therapy. Peritonitis, Tuberculous / etiology

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Tuberculosis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387522.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; B72HH48FLU / Infliximab
  •  go-up   go-down


28. Choi YW, Munden RF, Erasmus JJ, Park KJ, Chung WK, Jeon SC, Park CK: Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics; 2004 Jul-Aug;24(4):985-97; discussion 998
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis.
  • Radiation-induced lung disease (RILD) due to radiation therapy is common.
  • Radiologic manifestations are usually confined to the lung tissue within the radiation port and are dependent on the interval after completion of treatment.
  • However, the use of oblique beam angles and the development of newer irradiation techniques such as three-dimensional conformal radiation therapy can result in an unusual distribution of these findings.
  • Awareness of the atypical manifestations of RILD can be useful in preventing confusion with infection, recurrent malignancy, lymphangitic carcinomatosis, and radiation-induced tumors.
  • Such findings include the late appearance or enlargement of a pleural effusion; development of consolidation, a mass, or cavitation; and occlusion of bronchi within an area of radiation-induced fibrosis.
  • A comprehensive understanding of the full spectrum of these manifestations is important to facilitate diagnosis and management in cancer patients treated with radiation therapy.
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma / radiotherapy. Adult. Aged. Antineoplastic Agents / adverse effects. Antineoplastic Agents / pharmacology. Breast Neoplasms / radiotherapy. Bronchiectasis / etiology. Bronchiectasis / radiography. Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radiotherapy. Diagnosis, Differential. Disease Progression. Dose Fractionation. Esophageal Neoplasms / radiotherapy. Female. Hodgkin Disease / radiotherapy. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local / radiography. Neoplasms, Radiation-Induced / diagnosis. Radiation Tolerance / drug effects. Radiotherapy Dosage. Radiotherapy, Conformal / adverse effects

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright RSNA, 2004
  • (PMID = 15256622.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 59
  •  go-up   go-down


29. Torrejón Reyes PN, Frisancho O, Gómez A, Yábar A: [Malignant peritoneal mesothelioma]. Rev Gastroenterol Peru; 2010 Jan-Mar;30(1):82-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of a 58 year old man with diabetes mellitus type 2, arterial hypertension and smoking; without precedent of asbestos exposure.
  • Cytology: mesothelial cells with changes of type reagent, Block cell for tumour cells: negative.
  • Thoracic-abdominal CT: left side pleural effusion, severe ascites with thick epyplon.
  • The finds of the laparoscopy were interpreted like carcinomatosis or peritoneal tuberculosis.
  • The report of the peritoneal biopsy was informed as suggestive of undifferentiated carcinoma; the reappraisal with inmunohystochemic (calretinin +,cytokeratin +, vimentin +) indicated malignant peritoneal mesothelioma, type epithelial.
  • The patient was transferred to the Service of Oncology where they initiated chemotherapy with Cysplatin (CDDP) and died 20 days later.
  • The malignant mesothelioma peritoneal is a unfrequent entity, with limited therapeutic options; generally detected late, with a palliative treatment.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445731.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Peru
  •  go-up   go-down


30. Fang J, Sawa T, Maeda H: Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol; 2003;519:29-49
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
  • On the contrary, however, they can be utilized for macromolecular drug delivery to tumor.
  • Impaired reticuloendothelial/lymphatic clearance of macromolecules from the tumor, or lack of such clearance, is another unique characteristic of tumor tissue, which results intratumor retention of macromolecular drugs thus delivered (Figure 1).
  • Consequently, enhanced permeability and retention (EPR) effect is the basis for the selective targeting of macromolecular drugs to tumor, and the EPR concept is now utilized for selective delivery of many macromolecular anticancer agents in aqueous formation for i.v. or i.a. as well as oily formation for i.a. dosing, which is not possible for low-molecular-weight drugs because of rapid washout by capillary vascular blood flow.
  • In our laboratories, several promising macromolecular anticancer drugs after SMANCS, such as PEG-XO, PEG-DAO, PEG-ZnPP, were developed, warranting further investigation for clinical application.
  • More efficient drug delivery to tumor, especially of macromolecular drugs, may be possible by enhancing the EPR effect with the use of various vascular permeability mediators or potentiators.
  • Suppression of the EPR effect by the use of appropriate inhibitors or antidotes, such as the bradykinin antagonist HOE 140 and protease inhibitors or NOS inhibitors, may also be possible.
  • Also, by suppressing vascular permeability with antidotes such as the bradykinin antagonist HOE 140, pleural fluid in lung cancer and ascitic fluid in abdominal carcinomatosis may be controlled and the clinical course of cancer patients may be improved.
  • In summary, tumor vasculature can be an excellent target for delivery of macromolecular anticancer drugs; the most beneficial class of drugs in view of tumor-selective targeting based on the EPR effect in solid tumor as well as compliance of patients and ultimate therapeutic efficacy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Capillary Permeability / drug effects. Maleic Anhydrides / pharmacology. Neoplasms / blood supply. Neoplasms / drug therapy. Polystyrenes / pharmacology. Zinostatin / analogs & derivatives. Zinostatin / pharmacology
  • [MeSH-minor] Amino Acid Sequence. Humans. Inflammation Mediators / pharmacology. Molecular Sequence Data. Regional Blood Flow / drug effects. Vasoconstrictor Agents / pharmacology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12675206.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Inflammation Mediators; 0 / Maleic Anhydrides; 0 / Polystyrenes; 0 / Vasoconstrictor Agents; 0 / poly(maleic acid-styrene)neocarzinostatin; 9014-02-2 / Zinostatin
  • [Number-of-references] 64
  •  go-up   go-down






Advertisement